Digital Dose Inhalers Market

Digital Dose Inhalers Market (Product: Metered Dose Inhalers and Dry Powder Inhalers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Digital Dose Inhalers Market Outlook 2031

  • The global digital dose inhalers market was valued at US$ 2.23 Bn in 2021
  • The global market is projected to advance at a CAGR of 12.5% from 2022 to 2031
  • The global digital dose inhalers market is anticipated to reach more than US$ 7.22 Bn by 2031

Analysts’ Viewpoint on Digital Dose Inhalers Market Scenario

Digital dose inhalers, which feature sensors and wireless connectivity, help address the need for optimized adherence to maintenance medication in patients with respiratory diseases. Physicians tend to prescribe these products for respiratory diseases such as COPD and asthma. This is driving the digital dose inhalers market. Investment in technologically advanced products, such as smart inhalers, is expected to enable manufacturers to achieve high ROI. However, low awareness about digital dose inhalers among the population could hamper sales. Nevertheless, introduction of reimbursement plans to cushion healthcare expenditure is projected to lead to positive sentiment among patients toward effective treatment.

Digital Dose Inhalers Market

Digital Dose Inhalers Market Introduction

Digital dose inhalers are advanced, smart devices intended to treat and manage drug delivery for various respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Digital dose inhalers are used to provide a simple, accurate, and reliable dose counter, which enables patients to track adherence to their therapy. Increase in patient population, adoption of novel technologies, and surge in research & development in developed and developing countries are driving the global digital dose inhalers market. Furthermore, rise in prevalence of respiratory diseases such as asthma and COPD (chronic obstructive pulmonary disorder) across the globe and increase in geriatric population are projected to drive the global digital dose inhalers market in the next few years. Thus, demand for digital inhalers for chronic obstructive pulmonary disease is anticipated to increase substantially across the globe. Introduction of data integration with EHR (electronic health records) or EMR (electronic medical records) is a major trend in the global digital dose inhalers market. However, management of chronic airway diseases is 10% medication and 90% education. Inability of patients to effectively use inhaler devices can be largely ascribed to deficiencies in clinicians’ knowledge of inhaler techniques. Thus, lack of knowledge, awareness, and training required to instruct patients in proper usage of digital inhalers is restraining the global digital dose inhalers market.

Emerging economies such as India, China, Brazil, and Mexico offer significant opportunities in the global digital dose inhalers market. Presence of large geriatric population; government initiatives to improve healthcare sector; rise in research & development activities; and increase in pollution, allergens, and occupational dust are factors driving the market in these countries. The highest rate of hospitalization in India is for cardiac and respiratory problems, and for asthma in Bangladesh. In 2020, the WHO estimated geriatric population of around 1,000 million, with 700 million of them living in developing countries. This offers lucrative opportunities for market players.

Request a sample to get extensive insights into the Digital Dose Inhalers Market

COVID-19 Impact on Digital Dose Inhalers Market

The outbreak of COVID-19 has had a positive effect on the global digital dose inhalers market. Governments of affected countries gave instructions for the postponement of non-essential surgeries and patient visits. Respiratory support devices such as atomizers, life-support machines, oxygen generators, and monitors are among the majorly used medical devices in primary clinical treatment. Hence, COVID-19 has led to a surge in demand for these products. Furthermore, worsening of the pandemic situation affected the supply and demand gap and increased the demand for digital dose inhaler devices. Patients with asthma are at a higher risk of contracting COVID-19. As the virus continues to spread, hospitals are increasingly using metered dose inhaler. COVID-19 is sparking fear of medication shortage and panic buying, which could lead to a shortage of critical inhalers. Therefore, increase in panic buying, high risk of COVID-19 among patients with respiratory diseases, and high demand and supply gap are driving the global digital dose inhalers market.

Increase in Awareness and Penetration Augmenting Demand for Metered Dose Inhalers

In terms of product, the metered dose inhalers segment accounted for major share of the global digital dose inhalers market in 2021. This can be ascribed to the rise in penetration and product launch of metered dose inhalers; and increase in awareness about these products among patients. According to NCBI, the inherent multi-dose nature of MDIs makes them more affordable than most competing inhalation delivery systems. Thu, metered dose inhalers are considered highly popular inhalers to treat local respiratory diseases such as asthma and COPD.

Increase in regulatory approvals is driving the metered dose inhalers segment. For instance, in December 2018, AstraZeneca received approval from the European Commission (EC) for Bevespi Aerosphere, which is used in a pressurized metered dose inhaler (pMDI) indicated as maintenance dual bronchodilator treatment in adult patients with COPD. This approval enabled the company to add a technologically advanced product to its existing product offerings for patients in Europe.

Request a custom report on Digital Dose Inhalers Market

High Prevalence of Asthma to Boost Digital Dose Inhalers Market

In terms of application, the asthma segment accounted for significant share of the global digital dose inhalers market in 2021. This can be ascribed to high prevalence and product launches. According to the WHO, asthma was a major non-communicable disease in 2019. Asthma affected an estimated 262 million people and caused 455,000 deaths in 2019. According to the Asthma and Allergy Foundation of America, more than 26 million people in the U.S. suffer from asthma. Incidence of asthma has been increasing since the early 1980s in all ages, sexes, and racial groups.

Rise in launch of digital inhalers for asthma is driving the asthma segment. For instance, in January 2017, Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) approved two of its products for adolescent and adult patients with asthma. These products, i.e. AirDuo RespiClick (fluticasone propionate and salmeterol inhalation powder) and ArmonAir RespiClick (fluticasone propionate inhalation powder), include medication delivered via Teva’s RespiClick breath-activated, multi-dose dry powder inhaler (mDPI), which is also used with other approved medicines from Teva’s respiratory inhaler product portfolio.

Regional Outlook of Global Digital Dose Inhalers Market

North America dominated the global digital dose inhalers market in 2021. The region’s dominance of the global market can be ascribed to high prevalence and increase in incidence of COPD and asthma in the U.S. and Canada; well-established healthcare infrastructure; and high risk of lifestyle-related diseases. Furthermore, increase in trend of smoking in North America is propelling the risk of asthma. Smoking is directly responsible for around 90% of lung cancer deaths and nearly 80% of deaths caused by chronic obstructive pulmonary disease (COPD) including emphysema and chronic bronchitis. Additionally, robust product pipeline of key players is projected to drive the global digital dose inhalers market in North America.

Asia Pacific is anticipated to be the fastest growing market for digital dose inhalers during the forecast period. China dominated the digital dose inhalers market in the region in 2021. The digital dose inhalers market in India is likely to grow at a high CAGR during the forecast period. According to Lung India, a recent Indian study on Epidemiology of Asthma, Respiratory Symptoms and Chronic Bronchitis (INSEARCH) conducted on 85,105 men and 84,470 women from 12 urban and 11 rural sites in India, the rate of prevalence of asthma in India stands at 2.05% among individuals aged over 15 years, with a burden of around 18 million asthma patients across the country.

The digital dose inhalers market in Latin America and Middle East & Africa is likely to grow at a decent CAGR owing to the increase in respiratory disease patient pool and focus of manufacturers on the development of novel products.

Analysis of Key Players in Global Digital Dose Inhalers Market

This report includes vital information about the key players operating in the global digital dose inhalers market. Digital dose inhaler companies are focusing on strategies such as new product launches, divestiture, mergers & acquisitions (M&A), and partnerships to strengthen their position in the market. Novartis AG, AstraZeneca, Glenmark, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., 3M, Sensirion AG Switzerland, AptarGroup, Inc., Cipla, Inc., and H&T Presspart Manufacturing Ltd. are the prominent players operating in the global digital dose inhalers market.

Key Developments in Global Digital Dose Inhalers Market

  • In March 2022, the U.S. Food and Drug Administration gave the approval for the first generic of Symbicort (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of two common pulmonary health conditions to Mylan Pharmaceuticals, Inc.
  • In July 2019, Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) approved “ProAir Digihaler” inhalation powder, the first and only digital inhaler with built-in sensors, which connects to a companion mobile application and provides inhaler use information to people with asthma and COPD. ProAir Digihaler is used for the treatment or prevention of bronchospasm in patients aged four years and older with reversible obstructive airway disease, and for the prevention of exercise-induced bronchospasm (EIB) in patients aged four years and older.
  • In February 2019, 3M announced that it had completed the acquisition of M*Modal’s technology business for a total enterprise value of US$1 Bn. M*Modal’s technology business provides cloud-based, conversational artificial intelligence (AI)-powered systems. This is likely to expand the capabilities of 3M’s Health Information Systems business.

Each of these players has been profiled in the digital dose inhalers market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Digital Dose Inhalers Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 2.23 Bn

Market Forecast Value in 2031

More than US$ 7.22 Bn

Compound Annual Growth Rate (CAGR)

12.5%

Forecast Period

2022–2031

Historical Data Available for

2017–2021

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis/ranking by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Product
    • Metered Dose Inhalers
    • Dry Powder Inhalers
  • Application
    • Asthma
    • COPD (chronic obstructive pulmonary disease
    • Others

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Novartis AG
  • AstraZeneca
  • Glenmark
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd.
  • 3M
  • Sensirion AG Switzerland
  • AptarGroup, Inc.
  • Cipla, Inc.
  • H&T Presspart Manufacturing Ltd.

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global digital dose inhalers market in 2021?

The global digital dose inhalers market was valued at US$ 2.23 Bn in 2021.

How big will be the global digital dose inhalers market in 2031?

The global digital dose inhalers market is projected to reach more than US$ 7.22 Bn by 2031.

What will be the CAGR of the global digital dose inhalers market during the forecast period (2022–2031)?

The global digital dose inhalers market is anticipated to grow at a CAGR of 12.5% from 2022 to 2031.

Which are the prominent trends that affect market growth?

Increase in incidence of COPD and asthma is driving the global digital dose inhalers market

Which region will account for major share of the global market during the forecast period?

North America is expected to account for major share of the global digital dose inhalers market during the forecast period

Who are the prominent players in the global digital dose inhalers market?

Novartis AG, AstraZeneca, Glenmark, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., 3M, Sensirion AG Switzerland, AptarGroup, Inc., Cipla, Inc., and H&T Presspart Manufacturing Ltd.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Digital Dose Inhalers Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Product Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Digital Dose Inhalers Market Analysis and Forecast, 2017–2031

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Market Outlook

        5.1. Technological Advancements

        5.2. Key Industry Events (Mergers, Acquisitions, Product Launch , etc.)

        5.3. Epidemiology of Respiratory Diseases, such as Asthma, COPD (Chronic Obstructive Pulmonary Disease),etc.

    6. Global Digital Dose Inhalers Market Analysis and Forecast, by Product

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Product, 2017–2031

            6.3.1. Metered Dose Inhalers

            6.3.2. Dry Powder Inhalers

        6.4. Market Attractiveness Analysis, by Product

    7. Global Digital Dose Inhalers Market Analysis and Forecast, by Application

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Application, 2017–2031

            7.3.1. Asthma

            7.3.2. COPD (chronic obstructive pulmonary disease)

            7.3.3. Others

        7.4. Market Attractiveness Analysis, by Application

    8. Global Digital Dose Inhalers Market Analysis and Forecast, by Region

        8.1. Key Findings

        8.2. Market Value Forecast, by Region

            8.2.1. North America

            8.2.2. Europe

            8.2.3. Asia Pacific

            8.2.4. Latin America

            8.2.5. Middle East & Africa

        8.3. Market Attractiveness Analysis, by Region

    9. North America Digital Dose Inhalers Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. Market Value Forecast, by Product, 2017–2031

            9.2.1. Metered Dose Inhalers

            9.2.2. Dry Powder Inhalers

        9.3. Market Value Forecast, by Application, 2017–2031

            9.3.1. Asthma

            9.3.2. COPD (chronic obstructive pulmonary disease)

            9.3.3. Others

        9.4. Market Value Forecast, by Country, 2017–2031

            9.4.1. U.S.

            9.4.2. Canada

        9.5. Market Attractiveness Analysis

            9.5.1. By Product

            9.5.2. By Application

            9.5.3. By Country

    10. Europe Digital Dose Inhalers Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Product, 2017–2031

            10.2.1. Metered Dose Inhalers

            10.2.2. Dry Powder Inhalers

        10.3. Market Value Forecast, by Application, 2017–2031

            10.3.1. Asthma

            10.3.2. COPD (chronic obstructive pulmonary disease)

            10.3.3. Others

        10.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            10.4.1. Germany

            10.4.2. U.K.

            10.4.3. France

            10.4.4. Spain

            10.4.5. Italy

            10.4.6. Rest of Europe

        10.5. Market Attractiveness Analysis

            10.5.1. By Product

            10.5.2. By Application

            10.5.3. By Country/Sub-region

    11. Asia Pacific Digital Dose Inhalers Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Product, 2017–2031

            11.2.1. Metered Dose Inhalers

            11.2.2. Dry Powder Inhalers

        11.3. Market Value Forecast, by Application, 2017–2031

            11.3.1. Asthma

            11.3.2. COPD (chronic obstructive pulmonary disease)

            11.3.3. Others

        11.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.4.1. China

            11.4.2. Japan

            11.4.3. India

            11.4.4. Australia & New Zealand

            11.4.5. Rest of Asia Pacific

        11.5. Market Attractiveness Analysis

            11.5.1. By Product

            11.5.2. By Application

            11.5.3. By Country/Sub-region

    12. Latin America Digital Dose Inhalers Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Product, 2017–2031

            12.2.1. Metered Dose Inhalers

            12.2.2. Dry Powder Inhalers

        12.3. Market Value Forecast, by Application, 2017–2031

            12.3.1. Asthma

            12.3.2. COPD (chronic obstructive pulmonary disease)

            12.3.3. Others

        12.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.4.1. Brazil

            12.4.2. Mexico

            12.4.3. Rest of Latin America

        12.5. Market Attractiveness Analysis

            12.5.1. By Product

            12.5.2. By Application

            12.5.3. By Country/Sub-region

    13. Middle East & Africa Digital Dose Inhalers Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Product, 2017–2031

            13.2.1. Metered Dose Inhalers

            13.2.2. Dry Powder Inhalers

        13.3. Market Value Forecast, by Application, 2017–2031

            13.3.1. Asthma

            13.3.2. COPD (chronic obstructive pulmonary disease)

            13.3.3. Others

        13.4. Market Value Forecast, by Country/Sub-region, 2017–2031

            13.4.1. GCC Countries

            13.4.2. South Africa

            13.4.3. Israel

            13.4.4. Rest of Middle East & Africa

        13.5. Market Attractiveness Analysis

            13.5.1. By Product

            13.5.2. By Application

            13.5.3. By Country/Sub-region

    14. Competition Landscape

        14.1. Market Player - Competition Matrix (by tier and size of companies)

        14.2. Market Share/Position Analysis, by Company, 2021

        14.3. Company Profiles

            14.3.1. Novartis AG

                14.3.1.1. Company Overview

                14.3.1.2. Company Financials

                14.3.1.3. Growth Strategies

                14.3.1.4. SWOT Analysis

            14.3.2. AstraZeneca

                14.3.2.1. Company Overview

                14.3.2.2. Company Financials

                14.3.2.3. Growth Strategies

                14.3.2.4. SWOT Analysis

            14.3.3. Glenmark

                14.3.3.1. Company Overview

                14.3.3.2. Company Financials

                14.3.3.3. Growth Strategies

                14.3.3.4. SWOT Analysis

            14.3.4. GlaxoSmithKline plc

                14.3.4.1. Company Overview

                14.3.4.2. Company Financials

                14.3.4.3. Growth Strategies

                14.3.4.4. SWOT Analysis

            14.3.5. Teva Pharmaceutical Industries Ltd.

                14.3.5.1. Company Overview

                14.3.5.2. Company Financials

                14.3.5.3. Growth Strategies

                14.3.5.4. SWOT Analysis

            14.3.6. 3M

                14.3.6.1. Company Overview

                14.3.6.2. Company Financials

                14.3.6.3. Growth Strategies

                14.3.6.4. SWOT Analysis

            14.3.7. Sensirion AG Switzerland

                14.3.7.1. Company Overview

                14.3.7.2. Company Financials

                14.3.7.3. Growth Strategies

                14.3.7.4. SWOT Analysis

            14.3.8. AptarGroup, Inc.

                14.3.8.1. Company Overview

                14.3.8.2. Company Financials

                14.3.8.3. Growth Strategies

                14.3.8.4. SWOT Analysis

            14.3.9. Cipla, Inc.

                14.3.9.1. Company Overview

                14.3.9.2. Company Financials

                14.3.9.3. Growth Strategies

                14.3.9.4. SWOT Analysis

            14.3.10. H&T Presspart Manufacturing Ltd.

                14.3.10.1. Company Overview

                14.3.10.2. Company Financials

                14.3.10.3. Growth Strategies

                14.3.10.4. SWOT Analysis

    *Note: Financial details for companies that do not report this information in public domain might not be captured

    List of Tables

    Table 01: Epidemiology of Respiratory Diseases, such as Asthma, COPD (Chronic Obstructive Pulmonary Disease), etc.

    Table 02: Epidemiology of Respiratory Diseases, such as Asthma, COPD (Chronic Obstructive Pulmonary Disease), etc.

    Table 03: Global Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 04: Global Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 05: Global Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 06: North America Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 07: North America Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 08: North America Digital Dose Inhalers Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 09: Europe Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 10: Europe Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 11: Europe Digital Dose Inhalers Market Value (US$ Mn) Forecast, by End-user, 2017–2031

    Table 12: Asia Pacific Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 13: Asia Pacific Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 14: Asia Pacific Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 15: Latin America Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 16: Latin America Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 17: Latin America Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 18: Middle East & Africa Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 19: Middle East & Africa Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Product, 2017–2031

    Table 20: Middle East & Africa Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Application, 2017–2031

    List of Figures

    Figure 01: Global Digital Dose Inhalers Market Size (US$ Mn) and Distribution, by Region, 2021 and 2031

    Figure 02: Global Digital Dose Inhalers Market Revenue (US$ Mn), by Product, 2021

    Figure 03: Global Digital Dose Inhalers Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 04: Global Digital Dose Inhalers Market Value Share (%), by Product, 2021 and 2031

    Figure 05: Global Digital Dose Inhalers Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Metered Dose Inhalers, 2017–2031

    Figure 06: Global Digital Dose Inhalers Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Dry Powder Inhalers, 2017–2031

    Figure 07: Global Digital Dose Inhalers Market Attractiveness Analysis, by Product, 2017–2031

    Figure 08: Global Digital Dose Inhalers Market Value Share, by Application, 2021 and 2031

    Figure 09: Global Digital Dose Inhalers Market Attractiveness Analysis, by Application, 2017–2031

    Figure 10: Global Digital Dose Inhalers Market Value (US$ Mn) and Y-o-Y Growth, by Asthma, 2017–2031

    Figure 11: Global Digital Dose Inhalers Market Value (US$ Mn) and Y-o-Y Growth, by COPD (chronic obstructive pulmonary disease), 2017–2031

    Figure 12: Global Digital Dose Inhalers Market Value (US$ Mn) and Y-o-Y Growth, by Others, 2017–2031

    Figure 13: Global Digital Dose Inhalers Market Value Share, by Region, 2021 and 2031

    Figure 14: Global Digital Dose Inhalers Market Attractiveness Analysis, by Region, 2017–2031

    Figure 15: North America Digital Dose Inhalers Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031

    Figure 16: North America Digital Dose Inhalers Market Value Share (%), by Country, 2021 and 2031

    Figure 17: North America Digital Dose Inhalers Market Attractiveness Analysis, by Country, 2017–2031

    Figure 18: North America Digital Dose Inhalers Market Value Share, by Product, 2021 and 2031

    Figure 19: North America Digital Dose Inhalers Market Attractiveness Analysis, by Product, 2017–2031

    Figure 20: North America Digital Dose Inhalers Market Value Share Analysis, by Application, 2021 and 2031

    Figure 21: North America Digital Dose Inhalers Market Attractiveness Analysis, by Application, 2017–2031

    Figure 22: Europe Digital Dose Inhalers Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031

    Figure 23: Europe Digital Dose Inhalers Market Value Share (%), by Country / Sub-region, 2021 and 2031

    Figure 24: Europe Digital Dose Inhalers Market Attractiveness Analysis, by Country / Sub-region, 2017–2031

    Figure 25: Europe Digital Dose Inhalers Market Value Share, by Product, 2021 and 2031

    Figure 26: Europe Digital Dose Inhalers Market Attractiveness Analysis, by Product, 2017–2031

    Figure 27: Europe Digital Dose Inhalers Market Value Share Analysis, by Application, 2021 and 2031

    Figure 28: Europe Digital Dose Inhalers Market Attractiveness Analysis, by Application, 2017–2031

    Figure 29: Asia Pacific Digital Dose Inhalers Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031

    Figure 30: Asia Pacific Digital Dose Inhalers Market Value Share (%), by Country/Sub-region, 2021 and 2031

    Figure 31: Asia Pacific Digital Dose Inhalers Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

    Figure 32: Asia Pacific Digital Dose Inhalers Market Value Share, by Product, 2021 and 2031

    Figure 33: Asia Pacific Digital Dose Inhalers Market Attractiveness Analysis, by Product, 2017–2031

    Figure 34: Asia Pacific Digital Dose Inhalers Market Value Share Analysis, by Application, 2021 and 2031

    Figure 35: Asia Pacific Digital Dose Inhalers Market Attractiveness Analysis, by Application, 2017–2031

    Figure 36: Latin America Digital Dose Inhalers Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031

    Figure 37: Latin America Digital Dose Inhalers Market Value Share (%), by Country / Sub-region, 2021 and 2031

    Figure 38: Latin America Digital Dose Inhalers Market Attractiveness Analysis, by Country / Sub-region, 2017–2031

    Figure 39: Latin America Digital Dose Inhalers Market Value Share, by Product, 2021 and 2031

    Figure 40: Latin America Digital Dose Inhalers Market Attractiveness Analysis, by Product, 2017–2031

    Figure 41: Latin America Digital Dose Inhalers Market Value Share Analysis, by Application, 2021 and 2031

    Figure 42: Latin America Digital Dose Inhalers Market Attractiveness Analysis, by Application, 2017–2031

    Figure 43: Middle East & Africa Digital Dose Inhalers Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031

    Figure 44: Middle East & Africa Digital Dose Inhalers Market Value Share (%), by Country/Sub-region, 2021 and 2031

    Figure 45: Middle East & Africa Digital Dose Inhalers Market Attractiveness Analysis, by Country/Sub-region, 2017–2031

    Figure 46: Middle East & Africa Digital Dose Inhalers Market Value Share, by Product, 2021 and 2031

    Figure 47: Middle East & Africa Digital Dose Inhalers Market Attractiveness Analysis, by Product, 2017–2031

    Figure 48: Middle East & Africa Digital Dose Inhalers Market Value Share Analysis, by Application, 2021 and 2031

    Figure 49: Middle East & Africa Digital Dose Inhalers Market Attractiveness, by Application, 2017–2031

    Figure 50: Novartis AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2021

    Figure 51: Novartis AG R&D Intensity and Sales & Marketing Intensity - Company Level, 2017–2021

    Figure 52: Novartis AG Breakdown of Net Sales (%), by Region, 2021

    Figure 53: Novartis AG Breakdown of Net Sales (%), by Business Segment, 2021

    Figure 54: AstraZeneca Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2021

    Figure 55: AstraZeneca R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2021

    Figure 56: AstraZeneca Breakdown of Net Sales (%), by Region, 2021

    Figure 57: AstraZeneca Respiratory Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2021

    Figure 58: Glenmark (US$ Mn) Revenue, 2017–2021

    Figure 59: Distribution of Glenmark Revenue (%), by Region, 2021

    Figure 60: GlaxoSmithKline plc. Revenue (US$ Mn), 2017–2021

    Figure 61: GlaxoSmithKline plc. R&D Expenses (US$ Mn), 2017–2021

    Figure 62: GlaxoSmithKline plc. Breakdown of Net Sales (%), by Region, 2021

    Figure 63: GlaxoSmithKline plc. Breakdown of Net Sales (%), by Business Segment, 2021

    Figure 64: Teva Pharmaceutical Industries Ltd Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2021

    Figure 65: Teva Pharmaceutical Industries Ltd R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2021

    Figure 66: Teva Pharmaceutical Industries Ltd Breakdown of Net Sales (%), by Region, 2021

    Figure 67: 3M , Revenue (US$ Mn) & Y-o-Y Growth (%), 2016–2021

    Figure 68: 3M , R&D Expenses (US$ Mn) & Y-o-Y Growth (%), 2016-2021

    Figure 69: 3M, Breakdown of Net Sales (%), by Region, 2021

    Figure 70: 3M Breakdown of Net Sales (%), by Business Segment, 2021

    Figure 71: Sensirion AG Switzerland, Revenue (US$ Mn) & Y-o-Y Growth (%), 2016–2021

    Figure 72: Sensirion AG Switzerland, R&D Expenses (US$ Mn), 2017-2021

    Figure 73: Sensirion AG Switzerland, Breakdown of Net Sales (%), by Region, 2021

    Figure 74: Sensirion AG Switzerland, Breakdown of Net Sales (%), by Business Segment, 2021

    Figure 75: AptarGroup, Inc., Revenue (US$ Mn) & Y-o-Y Growth (%), 2016–2021

    Figure 76: AptarGroup, Inc., R&D Expenses (US$ Mn), 2016-2021

    Figure 77: AptarGroup, Inc., Breakdown of Net Sales (%), by Region, 2021

    Figure 78: AptarGroup, Inc., Breakdown of Net Sales (US$ Mn), by Business Segment, 2021

    Figure 79: Cipla Inc., Revenue (US$ Mn), 2017–2021

    Figure 80: Cipla Inc., Breakdown of Net Sales (%), by Region, 2021

    Figure 81: Cipla Inc., Breakdown of Net Sales (%), by Business Segment, 2021

Copyright © Transparency Market Research, Inc. All Rights reserved